Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection. Methods: We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area. Results: A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients. Conclusions: A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.
Abstract
Background/Aims: Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection. Methods: We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area. Results: A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients. Conclusions: A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.
참고문헌 (33)
- Kim MN, "Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region", J Gastroenterol, 48, pp.681~688 (2013)[DOI]
- Kim DY, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)[DOI]
- 정숙향, "Current status of hepatitis C virus infection and countermeasures in South Korea", Epidemiology and Health, 39, pp.1~7 (2017), 한국역학회[DOI]
- Kanda T, "New antiviral therapies for chronic hepatitis C", Hepatol Int, 4, pp.548~561 (2010)[DOI]
- Kanda T, "Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2", Dig Dis Sci, 56, pp.3335~3342 (2011)[DOI]
- "The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C"[URL]
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)[DOI]
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)[DOI]
- Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)[DOI]
- Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)[DOI]
- Zeuzem S, "Sofosbuvir and ribavirin in HCV genotypes 2 and 3", N Engl J Med, 370, pp.1993~2001 (2014)[DOI]
- Omata M, "Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial", J Viral Hepat, 21, pp.762~768 (2014)[DOI]
- Kao JH, "A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection", Liver Int, 36, pp.1101~1107 (2016)[DOI]
- Lam AM, "PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication", Antimicrob Agents Chemother, 54, pp.3187~3196 (2010)[DOI]
- Kanda T, "Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA", J Viral Hepat, 11, pp.479~487 (2004)[DOI]
- 오덕자, "Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes amongKorean Blood Donors", Annals of Laboratory Medicine, 32(3), pp.210~215 (2012), 대한진단검사의학회[DOI]
- Eun Ju Cho, "Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience", Clinical and Molecular Hepatology, 18(2), pp.219~224 (2012), 대한간학회
- YoungSikKim, "Risk Factors for Hepatitis C Virus Infection Among Koreans According to the Hepatitis C Virus Genotype", Journal of Korean Medical Science, 17(2), pp.187~192 (2002), 대한의학회
- Garcia-Samaniego J, "Factors associated with early virological response to peginterferon-<TEX>${\alpha}$<", TEX>-2a, World J Gastroenterol, pp.2013, 19[DOI]
- Bressler BL, "High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C", Hepatology, 38, pp.639~644 (2003)
- Chen JY, "IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-<TEX>${\alpha}$<", TEX> plus ribavirin therapy in Taiwanese chronic HCV infection, 2011, pp.12, 300~309
- Hsu CS, "Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy", Proc Natl Acad Sci U S A, 108, pp.3719~3724 (2011)[DOI]
- Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)[DOI]
- Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus", Nature, 461, pp.798~801 (2009)[DOI]
- Lyoo K, "Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin", J Clin Virol, 52, pp.363~366 (2011)[DOI]
- Jung YK, "Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans", J Clin Gastroenterol, 47, pp.644~650 (2013)[DOI]
- Kim SU, "Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection", PLoS One, 8, pp.e69166~ (2013)[DOI]
- Horoldt B, "Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection", Liver Int, 26, pp.650~659 (2006)[DOI]
- Carrion JA, "Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study", J Hepatol, 50, pp.719~728 (2009)[DOI]
- Huang CF, "Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C", J Infect Dis, 201, pp.751~759 (2010)[DOI]
- Thabut D, "Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease", Am J Gastroenterol, 101, pp.1260~1267 (2006)[DOI]
- Nudo CG, "Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C", Can J Gastroenterol, 20, pp.589~592 (2006)[DOI]
- Foster GR, "Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatmentexperienced patients with cirrhosis and hepatitis C virus genotype 2 infection", Gastroenterology, 149, pp.1462~1470 (2015)[DOI]